NCT07183293View on ClinicalTrials.gov

A Study on Peginterferon Alfa-2b Combined With NAs in Compensated HBV Cirrhosis

NANot yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

September 30, 2031

Conditions
HBV-related Liver Cirrhosis
Interventions
DRUG

Peginterferon alfa-2b combined with NAs

Subcutaneous injection therapy,Treatment will continue for 48 weeks, with follow-up assessments conducted every 12 weeks. The dosage will be adjusted based on the patient's disease status.

DRUG

NAs

Treatment will continue for 48 weeks, with follow-up assessments conducted every 12 weeks. The dosage will be adjusted based on the patient's disease status.

Trial Locations (2)

Unknown

Xiamen Hospital of Traditional Chinese Medicine, Xiamen

Zhongshan Hospital Affiliated to Xiamen University, Xiamen

All Listed Sponsors
lead

Xiamen Humanity Hospital

OTHER

NCT07183293 - A Study on Peginterferon Alfa-2b Combined With NAs in Compensated HBV Cirrhosis | Biotech Hunter | Biotech Hunter